ADCT - ADC Therapeutics targets $600M-$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts
2025-08-12 11:29:24 ET
More on ADC Therapeutics
- ADC Therapeutics SA 2025 Q2 - Results - Earnings Call Presentation
- ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript
- ADC Therapeutics SA (ADCT) Q1 2025 Earnings Call Transcript
- ADC reports data from lymphoma trial, streamlines operations
- ADC Therapeutics announces $100M private financing